Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 15Unknown 3Active not recruiting 3Withdrawn 2Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 17Lymphoid 9Myeloid 6CNS 6Classical hematology 4Sarcoma 3Plasma cell 2Breast 2Thoracic 1Other solid neoplasm 1Gynecologic 1Dermatologic 1

Conditions

Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 181pembrolizumab 156Pemetrexed 129Cisplatin 97Drug Therapy 67Paclitaxel 59osimertinib 56Magnetic Resonance Spectroscopy 50durvalumab 49Specimen Handling 49Radiotherapy 49Nivolumab 49atezolizumab 43Docetaxel 43Etoposide 40Bevacizumab 39Blood Specimen Collection 33tislelizumab 31Radiosurgery 31Gemcitabine 29130-nm albumin-bound paclitaxel 27Immunotherapy 25Immune Checkpoint Inhibitors 25cemiplimab 23Injections 23aflutinib 20Cetuximab 18Biopsy 18Standard of Care 17Platinum Compounds 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Filgrastim × Thoracic × Clear all
NCT07064018 2025-07-14

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

University of California, Irvine

Phase 1/2 Recruiting
67 enrolled
BreastGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡